RecruitingNot ApplicableNCT05192980

SIOPEN BIOPORTAL, An International Registry Linked to a Virtual Biobank for Patients With Peripheral Neuroblastic Tumours

Sponsor

Institut Curie

Enrollment

600 participants

Start Date

Nov 2, 2023

Study Type

INTERVENTIONAL

Conditions

Neuroblastoma Ganglioneuroma Ganglioneuroblastoma

Summary

The SIOPEN BIOPORTAL is a prospective non-therapeutic multi-centre international study aimed at developing an international Registry linked to a Virtual Biobank for all the patients with peripheral neuroblastic tumor within countries of the SIOPEN network. The overall aim of this study is to provide a GDPR-compliant framework to collect basic clinical annotations, biological and genetic features and information about the location on biospecimens for all the patients with a peripheral neuroblastic tumor including neuroblastoma, ganglioneuroblastoma and ganglioneuroma in the SIOPEN network. This study will support data and sample management and intensify cross-borders data and sample sharing fostering translational and clinical research. The post-hoc hypothesis formulated based on the data generated in this study will be used as statistical basis for future precision medicine programs based on improved biological characterization, patient stratification and therapeutic management.

Eligibility

Plain Language Summary

Simplified for easier understanding

This is an international registry and biobank study collecting biological samples and clinical data from children, adolescents, and young adults with neuroblastoma or related tumors (called peripheral neuroblastic tumors). The goal is to build a global resource to improve research and treatment for these rare childhood cancers. **You may be eligible if...** - You or your child has been diagnosed with neuroblastoma, ganglioneuroblastoma, or ganglioneuroma - The diagnosis was recent, or this is a relapse or progression and the patient has not yet been registered - The patient or parent/guardian is able to give written consent **You may NOT be eligible if...** - You are an adult patient with olfactory neuroblastoma - The tumor originates in the central nervous system (a different type classified separately) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNo Intervention NA

Additional blood sampling (not mandatory)

Locations(38)

Fakultni nemocnice v Motole

Prague, Czechia

CHU Amiens

Amiens, France

Chu Angers

Angers, France

Hôpital Jean Minjoz

Besançon, France

Hôpital des enfants

Bordeaux, France

Chru Brest

Brest, France

CHU CAEN - Fédération de cancérologie - niveau 21

Caen, France

CHU D'Estaing de CLERMONT FERRAND

Clermont-Ferrand, France

DIJON Hôpital d'enfants

Dijon, France

Chu Grenoble

Grenoble, France

Centre Oscar Lambret

Lille, France

Centre Léon Bérard

Lyon, France

Hôpital d'Enfants de la Timone

Marseille, France

Hôpital Arnaud de Villeneuve

Montpellier, France

Chr Nantes

Nantes, France

CHU NICE

Nice, France

Institut Curie

Paris, France

Hôpital Armand Trousseau

Paris, France

Hôpital Jean Bernard

Poitiers, France

Chu Reims

Reims, France

Chu Hopital Sud

Rennes, France

Hôpital Charles NICOLLE

Rouen, France

Hôpital Nord

Saint-Etienne, France

Hôpital Hautepierre-CHU Strasbourg

Strasbourg, France

Hôpital des Enfants

Toulouse, France

Hôpital Clocheville

Tours, France

CHU NANCY- Hôpital d'Enfants

Vandœuvre-lès-Nancy, France

Institut Gustave Roussy

Villejuif, France

Oslo Universitetssykehus

Oslo, Norway

Kantonsspital Aarau AG

Aarau, Switzerland

Universitäts-Kinderspital beider Basel UKBB

Basel, Switzerland

Ospedale San Giovanni

Bellinzona, Switzerland

Inselspital Bern

Bern, Switzerland

HUG Hôpitaux Universitaires Genève

Geneva, Switzerland

CHUV, Centre hospitalier universitaire vaudois

Lausanne, Switzerland

Kinderspital Zentralschweiz, Luzern

Lucerne, Switzerland

Ostschweizer Kinderspital

Sankt Gallen, Switzerland

Universitäts-Kinderspital Zürich

Zurich, Switzerland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05192980

Related Trials

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296177 locations

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

NCT069958721 location